SPY327.95-2.03 -0.62%
DIA265.33-1.26 -0.47%
IXIC11,029.16-156.44 -1.40%

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $54

Citigroup maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $56 to $54.

Benzinga · 06/30/2020 11:44
Citigroup maintains Apellis Pharmaceuticals (NASDAQ: APLS) with a Buy and lowers the price target from $56 to $54.